ZIVO BIOSCIENCE INC - ZIVO STOCK NEWS

ZIVO Bioscience, Inc. (OTCQB: ZIVO) reports favorable results from a 42-day study of its coccidiosis treatment in broiler chickens. The study, conducted with a major global animal health company, showed that ZIVO's non-antibiotic, immune-modulating product significantly improved growth performance and reduced clinical signs of disease when used in combination with existing treatments. Chickens treated with ZIVO's product alongside an ionophore or vaccination achieved feed conversion ratios comparable to healthy, uninfected birds. This demonstrates the product's potential to enhance current treatment options and its standalone treatment capabilities for coccidiosis, a major challenge in poultry production.

ZIVO Bioscience (NASDAQ: ZIVO) announced the start of a 42-day confirmatory study in partnership with a major global animal health company to validate its non-antibiotic coccidiosis treatment for broiler chickens. This study, building on previous positive results, aims to ensure the product's effectiveness under commercial poultry production conditions. The study compares ZIVO's product with traditional ionophore-based treatments and explores combinations with coccidiosis vaccines. The goal is to provide a sustainable, antibiotic-free solution to address the $10 billion annual loss in the poultry industry due to coccidiosis. The results are expected by September.

Zivo Bioscience, Inc. announces positive findings from a 42-day coccidiosis challenge study, demonstrating the impact of its product on broiler production. The product reduces intestinal damage caused by the Eimeria parasite, leading to improved feed utilization and a better Feed Conversion Ratio (FCR), which drives profitability. These results position ZIVO's product as a potential game-changer in the poultry industry, offering improved outcomes at cost parity or better.

Zivo Bioscience, Inc. (ZIVO) has successfully uplisted its common stock from the OTC Pink Market to the OTCQB Venture Market, under the ticker symbol 'ZIVO'. This move is aimed at enhancing visibility, improving market access, and increasing liquidity for shareholders. The OTCQB listing requires compliance with higher standards, financial reporting with the SEC, minimum bid price test, audited financials, and company verification.

Zivo Bioscience, Inc. announces positive results from a 42-day coccidiosis challenge study, demonstrating the effectiveness of its immune-modulating treatment for broiler chickens. The study showed that the product candidate is comparable to a market-leading anticoccidial product containing antibiotics and chemicals. Zivo will pursue a partnership with a global animal health company for commercializing its coccidiosis product.

Zivo Bioscience, Inc. is conducting a 42-day study to validate the efficacy of its immune-modulating treatment for coccidiosis in broiler chickens. The study aims to confirm the positive effects of Zivo's non-antibiotic alternative, including reduced mortality and improved bird growth rates. The study will also analyze secondary benefits such as protection of intestinal tissue and reduction of pathogenic bacteria.

Zivo Bioscience announces a 1-for-6 reverse stock split to regain compliance with Nasdaq listing requirements.

Zivo Bioscience, Inc. announces participation in the 8th Annual Dawson James Small Cap Growth Conference.

ZIVO Bioscience announces positive results from coccidiosis trial in broiler chickens, demonstrating statistically significant improvements in broiler health. The product candidate showed potential to mitigate the effects of coccidiosis through a non-antibiotic mechanism of action. ZIVO plans to launch the final phase of validation with results expected by the end of 2023. The company remains confident in the stability and effectiveness of its product candidate, presenting a disruptive solution to coccidiosis in the poultry industry.